ScienceDaily (Oct. 6, 2011) — A research alliance of Heidelberg University Hospital and the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), jointly with colleagues of the Helmholtz Center for Environmental Research in Leipzig, has discovered a new metabolic pathway which makes malignant brain tumors (gliomas) more aggressive and weakens patients' immune systems. Using drugs to inhibit this metabolic pathway is a new approach in cancer treatment.
The group's results have been published in the journal Nature.
Glioma is the most frequent and most malignant brain tumor in adults. In Germany, about 4,500 people are newly diagnosed with glioma every year. About 75 percent of such tumors are considered particularly aggressive with an average life expectancy of eight months to two years. The standard treatment is surgery to remove the tumor as completely as possible, followed by radiotherapy, usually in combination with chemotherapy. However, results are unsatisfactory, because these tumors are very resilient and soon start growing back. Therefore, there is an urgent need for new treatment approaches.
Tumors grow more aggressively and immune system is weakened
The Helmholtz Junior Research Group "Experimental Neuroimmunology" led by Professor Dr. Michael Platten of DKFZ and the Department of Neurooncology of Heidelberg University Hospital and the National Center for Tumor Diseases (NCT) headed by Professor Dr. Wolfgang Wick have come across the kynurenin molecule in their studies of human cancer cells and in the mouse model. Kynurenin is formed when the amino acid tryptophan -- a protein component taken in with food -- is broken down in the body. "We have been able to detect increased levels of kynurenin in cancer cells of glioma patients with particularly aggressive tumors," Professor Michael Platten explained. The current research results from Heidelberg show that this link also appears to exist in other types of cancer such as cancers of the bladder, bowel or lungs.
READ MORE: http://www.sciencedaily.com/releases/2011/10/111006102615.htm